Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease

Neurobiology of Disease

Volumn 39, Issue 2, 2010, Pages 156-168

  Ding, Yun ^a,b   Qiao, Aimin ^a,b   Fan, Guo Huang ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; Alzheimer's disease; Amyloid precursor protein; Indirubin 3' monoxime; Memory; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN 3' MONOXIME; INDIRUBIN DERIVATIVE; INDOLE DERIVATIVE; PRESENILIN 1; SYNAPTOPHYSIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNOREACTIVITY; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SPATIAL MEMORY; SYSTEMIC THERAPY; TRANSGENIC MOUSE; TREATMENT DURATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; CELL COUNT; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; INDOLES; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MICROGLIA; NEOCORTEX; NEUROPSYCHOLOGICAL TESTS; OXIMES; PEPTIDE FRAGMENTS; PRESENILIN-1; SYNAPTOPHYSIN; TAU PROTEINS;

EID: 77953718220     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.03.022     Document Type: Article

References (54)

1. Aplin A.E., Gibb G.M., Jacobsen J.S., Gallo J.M., Anderton B.H. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J. Neurochem. 1996, 67:699-707.
2. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
3. Christensen M.A., Zhou W., Qing H., Lehman A., Philipsen S., Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell. Biol. 2004, 24:865-874.
4. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 2006, 6:579-595.
5. Cruz J.C., Kim D., Moy L.Y., Dobbin M.M., Sun X., Bronson R.T., Tsai L.H. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J. Neurosci. 2006, 26:10536-10541.
6. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 1987, 78:151-164.
7. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390.
8. Deacon R.M., Cholerton L.L., Talbot K., Nair-Roberts R.G., Sanderson D.J., Romberg C., Koros E., Bornemann K.D., Rawlins J.N. Age-dependent and -independent behavioral deficits in Tg2576 mice. Behav. Brain Res. 2008, 189:126-138.
9. Ding Y., Qiao A., Wang Z., Goodwin J.S., Lee E.S., Block M.L., Allsbrook M., McDonald M.P., Fan G.H. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 2008, 28:11622-11634.
10. Edbauer D., Winkler E., Regula J.T., Pesold B., Steiner H., Haass C. Reconstitution of gamma-secretase activity. Nat. Cell Biol. 2003, 5:486-488.
11. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
12. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
13. Fischer A., Sananbenesi F., Pang P.T., Lu B., Tsai L.H. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 2005, 48:825-838.
14. Frame S., Cohen P., Biondi R.M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 2001, 7:1321-1327.
15. Frautschy S.A., Horn D.L., Sigel J.J., Harris-White M.E., Mendoza J.J., Yang F., Saido T.C., Cole G.M. Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. J. Neurosci. 1998, 18:8311-8321.
16. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
17. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
18. Irie K., Murakami K., Masuda Y., Morimoto A., Ohigashi H., Ohashi R., Takegoshi K., Nagao M., Shimizu T., Shirasawa T. Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. J. Biosci. Bioeng. 2005, 99:437-447.
19. Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T., Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 1992, 148:202-206.
20. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 1989, 24:173-182.
21. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17:157-165.
22. Jankowsky J.L., Slunt H.H., Gonzales V., Jenkins N.A., Copeland N.G., Borchelt D.R. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol. Aging 2004, 25:885-892.
23. Kameswaran T.R., Ramanibai R. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells. Biomed. Pharmacother. 2009, 63:146-154.
24. Kleiner J., Altshuler L., Hendrick V., Hershman J.M. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J. Clin. Psychiatry 1999, 60:249-255.
25. Knafo S., Alonso-Nanclares L., Gonzalez-Soriano J., Merino-Serrais P., Fernaud-Espinosa I., Ferrer I., DeFelipe J. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb. Cortex 2009, 19:586-592.
26. Knobloch M., Mansuy I.M. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol. Neurobiol. 2008, 37:73-82.
27. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 2001, 276:251-260.
28. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 2001, 158:1345-1354.
29. McGeer E.G., McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des. 1999, 5:821-836.
30. Meda L., Baron P., Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging 2001, 22:885-893.
31. Mehes G., Lorch T., Ambros P.F. Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis. Cytometry 2000, 42:357-362.
32. Melnikova I. Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 2007, 6:341-342.
33. Michel G., Mercken M., Murayama M., Noguchi K., Ishiguro K., Imahori K., Takashima A. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim. Biophys. Acta 1998, 1380:177-182.
34. Morrison J.H., Hof P.R. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog. Brain Res. 2002, 136:467-486.
35. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 1997, 56:70-78.
36. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 1998, 797:267-277.
37. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
38. Rouleau I., Salmon D.P., Butters N., Kennedy C., McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn. 1992, 18:70-87.
39. Salehi A., Delcroix J.D., Mobley W.C. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 2003, 26:73-80.
40. Selenica M.L., Jensen H.S., Larsen A.K., Pedersen M.L., Helboe L., Leist M., Lotharius J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 2007, 152:959-979.
41. Sereno L., Coma M., Rodriguez M., Sanchez-Ferrer P., Sanchez M.B., Gich I., Agullo J.M., Perez M., Avila J., Guardia-Laguarta C., Clarimon J., Lleo A., Gomez-Isla T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 2009, 35:359-367.
42. Sharma P., Sharma M., Amin N.D., Albers R.W., Pant H.C. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:11156-11160.
43. Stalder M., Phinney A., Probst A., Sommer B., Staufenbiel M., Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 1999, 154:1673-1684.
44. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
45. Takashima A. Amyloid-beta, Tau, and Dementia. J. Alzheimers Dis. 2009.
46. Tsai L.H., Delalle I., Caviness V.S., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423.
47. Uemura K., Kuzuya A., Shimozono Y., Aoyagi N., Ando K., Shimohama S., Kinoshita A. GSK3beta activity modifies the localization and function of presenilin 1. J. Biol. Chem. 2007, 282:15823-15832.
48. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
49. Weldon D.T., Rogers S.D., Ghilardi J.R., Finke M.P., Cleary J.P., O'Hare E., Esler W.P., Maggio J.E., Mantyh P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 1998, 18:2161-2173.
50. Wen Y., Planel E., Herman M., Figueroa H.Y., Wang L., Liu L., Lau L.F., Yu W.H., Duff K.E. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 2008, 28:2624-2632.
51. Wen Y., Yu W.H., Maloney B., Bailey J., Ma J., Marie I., Maurin T., Wang L., Figueroa H., Herman M., Krishnamurthy P., Liu L., Planel E., Lau L.F., Lahiri D.K., Duff K. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 2008, 57:680-690.
52. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 1996, 92:232-241.
53. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
54. Yuskaitis C.J., Jope R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal. 2009, 21:264-273.